Quarterly report pursuant to Section 13 or 15(d)

Note 13 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.20.4
Note 13 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Revenues, net $ 224,253 $ 184,934 $ 428,452 $ 368,177
Operating income 50,995 36,992 100,087 70,317
Costs recognized on sale of acquired inventory     (23) 0
Corporate general, selling, and administrative expenses (83,116) (68,030) (155,714) (137,040)
Operating Segments [Member]        
Operating income 88,353 61,847 167,379 122,285
Costs recognized on sale of acquired inventory (23) 0 (23) 0
Amortization of acquisition related intangible assets (15,027) (15,108) (30,528) (30,008)
Acquisition related expenses (4,421) 881 (4,558) (429)
Stock based compensation (16,225) (10,618) (29,558) (19,418)
Restructure costs (142) 0 (142) 0
Operating Segments [Member] | Protein Sciences [Member]        
Revenues, net 172,179 141,517 326,625 282,512
Operating income 80,246 60,872 150,598 120,410
Operating Segments [Member] | Diagnostics and Genomics [Member]        
Revenues, net 52,469 43,846 102,595 86,397
Operating income 8,107 975 16,781 1,875
Intersegment Eliminations [Member]        
Revenues, net (395) (429) (768) (732)
Corporate, Non-Segment [Member]        
Corporate general, selling, and administrative expenses $ (1,520) $ (12) $ (2,482) $ (2,113)